SGD Pharma, global market specialist in moulded glass primary packaging solutions for the pharmaceutical industry, has opened a new siliconisation operation at its Saint-Quentin Lamotte (SQLM) plant.
SGD Pharma
The company enhances its range of in-house services by internalising its glass siliconisation offer, further ensuring responsiveness, security of supply and improved flexibility of vial sizes.
SGD Pharma
Glass vials are regularly used for pharmaceutical packaging, though there is a growing market need for primary packaging that is suited to more sensitive, aggressive and viscous drug products. The application of a micro-layer silicone-based internal coating to the container provides a protective barrier that minimises interaction between the drug product and the primary packaging, while preserving the integrity of sensitive therapeutic products.
SGD Pharma’s treatment uses an optimised spraying process that provides uniform coverage of the vial surface, ensuring a higher performance of the internal silicone thin-layer. The process is executed with rigorous quality control under an ISO 8 clean room, in an ISO 15378 certified facility.
This new operation at SQLM is suitable for all glass types in vial sizes ranging from 3ml to 500ml in both clear and amber glass, at a high processing capacity. The treatment is for a wide variety of market applications including: anti-infectives, parenteral nutrition, diagnostics, animal health and oncology to name a few.
More details on the new line at SQLM and the benefits of internal siliconisation will be showcased by SGD Pharma on its booth (B60&B62) at Pharmapack 2024.